




THE REPUBLIC OF CYPRUS

Department of Registrar of Companies and Official Receiver

**ΚΥΠΡΙΑΚΟ ΓΡΑΦΕΙΟ ΔΙΠΛΩΜΑΤΩΝ
ΕΥΡΕΣΙΤΕΧΝΙΑΣ
THE PATENT OFFICE OF CYPRUS**

**ΑΡΙΘΜΟΣ ΔΗΜΟΣΙΕΥΣΗΣ CY1681
PUBLICATION NUMBER**

ΑΡΙΘΜΟΣ ΔΗΜΟΣΙΕΥΣΗΣ
ΓΡΑΦΕΙΟΥ ΔΙΠΛΩΜΑΤΩΝ ΕΥΡΕΣΙΤΕΧΝΙΑΣ
ΗΝΩΜΕΝΟΥ ΒΑΣΙΛΕΙΟΥ
UK PATENT OFFICE
PUBLICATION NUMBER GB2191494

Το έγγραφο που παρουσιάζεται πιο κάτω καταχωρήθηκε στο «Γραφείο Διπλωμάτων Ευρεσιτεχνίας» στην Αγγλία σύμφωνα με το Νόμο Κεφ. 266 πριν την 1^η Απριλίου 1998. Δημοσίευση έγινε μετέπειτα από το Γραφείο Διπλωμάτων Ευρεσιτεχνίας του Ηνωμένου Βασιλείου μόνο στην Αγγλική γλώσσα.

The document provided hereafter was filed at "The Patent Office" in England under the law CAP.266 before the 1st of April 1998. It was published afterwards by the UK patent office only in English.

(12) UK Patent Application (19) GB (11) 2 191 494 (13) A
(43) Application published 16 Dec 1987

(21) Application No 8713650

(22) Date of filing 11 Jun 1987

(30) Priority data

(31) 873884

(32) 13 Jun 1986

(33) US

(71) Applicant

Oncogen

(Incorporated in USA-Washington)

3005, First Avenue, Seattle, Washington 98121, United States of America

(72) Inventors

Jeffrey A. Ledbetter

Edward A. Clark

(74) Agent and/or Address for Service

Langner Parry,

52-54 High Holborn, London WC1V 6RR

(51) INT CL⁴

C12N 5/00 // C07K 3/14

(52) Domestic classification (Edition I):

C3H F2AC

C6F HA2

C6Y 404 501

U1S 1337 2411 C3H C6F

(56) Documents cited

J Immunology 1 Feb 1987 Vol 138 No 3 pages 788-94

Proceedings of the National Academy of Science USA

1986 Vol 83 No 12 pages 4494-8

Cancer Immunology and Immunotherapy 1985 Vol 20 No 1 pages 23-8

International Journal of Cancer 1985 Vol 36 Chan et al page 329

Journal of Experimental Medicine 1984 Vol 160 pages 1919-1925

Journal of Experimental Medicine 1979 Vol 149 pages 1424-1433

(58) Field of search

C3H

C6F

Selected US specifications from IPC sub-class C12N

C12P

(54) 50 kd B-cell receptor, ligands and monoclonal antibodies thereto

(57) The B-cell receptor, Bp50, is a 50 kilodalton polypeptide, that functions in B-cell proliferation. Ligands, such as lymphokines, antibody molecules or the F_v fragments of antibody molecules that bind to Bp50, augment the proliferation of activated B-cells and can be used to regulate B-cell proliferation of differentiation. Toxic substances can be bound to the ligand to suppress proliferation.


The ligands can be used in conjunction with a second ligand that binds Bp35, a 35 kd B-cell surface antigen which is involved in progression from G₀ to G₁ of the cell cycle.

GB 2 191 494 A

1/10

Figure 1.

Red Anti-Bp35 vs.
Green Anti-Bp50



Peripheral
Blood




Tonsil



2/10

Figure 2.



3/10

Figure 3.





Figure 4.



5/10

Figure 5.






Figure 6.




7/10

Figure 7.




8/10

Figure 8.




9/10

Figure 9.



10/10

Figure 10.



SPECIFICATION

Ligands and methods for augmenting B-cell proliferation

5 1. INTRODUCTION 5

The present invention is directed to ligands, such as antibody molecules or fragments of antibody molecules or other ligands such as lymphokines which bind to a 50kDa B-cell surface marker, herein referred to as Bp50, that functions in B-cell proliferation but not in early B-cell activation. The present invention is also directed to the Bp50 B-cell antigen itself. In a particular embodiment of the present invention, a monoclonal antibody, G28-5, is described that defines Bp50 and appears to play a role in the proliferation of activated B-cells but has no detectable effect on the proliferation of resting B-cells.

The ligands, such as antibodies, lymphokines and fragments thereof of the present invention can be used to direct and regulate human B-cell proliferation and/or differentiation. In addition, the ligands of the present invention may be modified by the attachment of other compounds which can be used in the treatment and/or detection of malignant cells that express the Bp50 antigen.

2. BACKGROUND OF THE INVENTION 20

The activation of resting B-cells from G_0 to G_1 phase of the cell cycle and the subsequent induction of activated B-cells to proliferate are distinct steps requiring distinct regulatory mechanisms. Some agents, including murine B-cell stimulating factor-pl (BSF-pl) (Rabin, et al., 1985, *Proc. Nat. Acad. Sci. USA* 82, 2935-2939) or low doses of anti-immunoglobulin (anti-Ig) (DeFranco, et al., 1985, *J. Immunol.* 135:87-94; Wetzel, et al., 1984, *J. Immunol.* 133:2327-2332; DeFranco, et al., 1982, *J. Exp. Med.* 155:1523-1536; Muraguchi, et al., 1984, *J. Immunol.* 132:176-180), are "activation" or "competence" factors. That is, they induce B-cells to enlarge, synthesize more RNA, and enter G_1 , but alone they do not induce DNA synthesis in B-cells. Other "growth" factors, such as human B-cell growth factor (BCGF) and interleukin-2 (IL-2) cause activated B-cells to traverse the cell cycle and enter S phase do not trigger resting B-cells (Kehrl, et al., 1984, *Immunol. Rev.* 18:75-96; Muraguchi, et al., 1984, *J. Immunol.* 132:176-180; Zubler, et al. 1984, *J. Exp. Med.* 160:1170-1183; Jung, et al., 1984, *J. Exp. Med.* 160:1597-1604).

A number of factors that promote the growth of B-cells have now been described by investigators of both murine and human systems. These include B-cell growth factors (BCGF) derived from several different sources including T-cell lines or hybridomas, B-cell lines, or dendritic cells. Although both interleukin-1 (IL-1) and interleukin-2 (IL-2) have been shown to augment B-cell growth, they apparently are distinct from certain BCGFs. For instance, monoclonal antibodies (mAb) to a murine BCGF (O'Hara, et al., 1985, *Nature (Lond.)* 315:333) or human BCGF (Ambrus, et al., 1985, *J. Exp. Med.* 162:1319) block BCGF activity but not IL-1 or IL-2 activity. Although distinct from IL-1 or IL-2, the BCGFs themselves appear to be heterogeneous based on biochemical data and differential activity on different B-cell subsets or costimulation assays. For instance, 60-kilodalton (kDa) high-molecular-weight human BCGF, BCGF (high), has been identified that is distinct from a 12-kDa low-molecular-weight form, BCGF (low) (Ambrus, et al., 1985, *J. Clin. Invest.* 75:732). The cDNA encoding a 20-kDa murine BCGF, tentatively designated B-cell stimulating factor pl (BSF-pl), has recently been cloned and sequenced (Noma et al., 1986, *Nature* 319:640). The recombinant lymphokine not only has BCGF activity but can also activate resting B-cells and induce the differentiation of IgG₁ producing cells; thus it differs from human BCGF (high) and BCGF (low) both in its molecular weight and in its range of activity.

These activation and growth signals presumably regulate cells by interacting with specific B-cell surface structures. In addition to the antigen-specific signal through surface Ig, several other candidate B-cell surface polypeptides have been identified that may in some way function in the activation or growth of B-cells. For instance, the cell surface receptors for IL-1 (Dower, et al., 1985, *J. Exp. Med.* 160:501) and IL-2 (Robb et al., 1984, *J. Exp. Med.* 160:1126) have been characterized, and recently functional IL-2 receptors have been identified on B-cells (Zubler, et al., 1984, *J. Exp. Med.* 160:1170; Jung, et al., 1984, *J. Exp. Med.* 160:1597; Muraguchi, et al., 1985, *J. Exp. Med.* 161:181). However, receptors for B-cell growth and activation factors have yet to be fully characterized. Several candidate B-cell surface polypeptides have been identified that may in some way function in the activation or growth of B-cells. For example, Subbarao and Mosier (Subbarao, et al., 1983, *Immunol. Rev.* 69:81-97) found that monoclonal antibodies (mAb) to the murine B-cell antigen Lyb2 activate B-cells, and recently evidence has been presented suggesting Lyb2 may be the receptor for BSF-pl (Yakura, 1985, *Fed. Proc.* 44:1532). Similarly, we have found that appropriate mAb (1F5) to a 35 kDa polypeptide, Bp35, activates human B-cells from G_0 into G_1 (Clark, et al., 1985, *Proc. Nat. Acad. Sci. USA* 82:1766-1770; Gollay, et al., 1985, *J. Immunol.* 135:3795-3801). Aggregated C3d or antibodies to the 140 kDa C3d receptor, Bp140, cause proliferation of B-cells that are T-cell dependent (Melchers, et

al., 1985, Nature 317:264-267; Nemerow, et al., 1985, J. Immunol. 135:3068-3073; Frade et al., 1985, Eur. J. Immunol. 15:73-76). Although BCGFs have been identified in both mouse and man, the receptors for these factors have not yet been isolated. Wang and coworkers (Wang, et al., 1979, J. Exp. Med. 149:1424-1433) made a polyclonal antisera that identified a 54-kDa polypeptide (gp54) on human B-cells and showed that the rabbit antisera to gp54 induced tonsillar B-cells to divide. Recently, Jung and Fu (Jung, et al., 1984, J. Exp. Med. 160:1919-1924) isolated a mAb (AB-1) to a 55-kDa antigen restricted to activated B-cells that blocks BCGF-dependent proliferation. However, whether or not either anti-gp54 or AB-1 recognize a BCGF receptor is not yet known.

3. SUMMARY OF THE INVENTION

The present invention is directed to ligands which (a) bind to Bp50, a 50kDa B-cell specific surface polypeptide described herein, and (b) augment the proliferation of activated B-cells. The invention is also directed to the Bp50 antigen itself, which is defined by monoclonal antibody G28-5 and functions in proliferation of activated B-cells. In addition the invention is directed to ligands which bind to Bp50, but do not demonstrate a biological effect or function such as augmentation of the proliferation of activated B-cells.

The ligands of the present invention include antibody molecules, monoclonal antibody molecules and fragments of these antibody molecules which contain the antigen combining site or chemically modified antibodies and fragments; such fragments include but are not limited to the Fv, Fab, F(ab')₂, Fab' and the like. In addition, the ligands of the present invention comprise lymphokines, which can include but are not limited to human B-cell growth factors as well as chemically modified lymphokines. The ligands of the present invention can be chemically modified, for example by linking or coupling a compound to the ligand. Such compounds include but are not limited to cytotoxic agents, therapeutic agents, chemotherapeutic agents, labels such as radiolabels, dye, enzymes, radiopaque compounds, and the like. The ligands of the present invention can in their modified or unmodified form, be used to direct, regulate and modify human B-cell proliferation and/or differentiation.

The present invention is based upon the discovery that two human B-cell differentiation antigens, Bp35 and the B-cell antigen described herein, Bp50, apparently play distinctive roles as signal receptors in B-cell activation. Monoclonal antibodies (mAb) to Bp35 and Bp50 both deliver positive signals to B-cells that stimulate their transition through the cell cycle. MAb to Bp35, like anti-Ig antibodies, functions principally to activate resting B-cells to become competent to enter the G₁ phase of the cell cycle. In contrast, a monoclonal antibody described herein or its F(ab')₂ fragment to Bp50, a 50-kDa polypeptide expressed on all B-cells, functions to stimulate activated B-cells to traverse the cell cycle and augments the proliferation of activated B-cells. Monoclonal antibodies to Bp35, like anti-Ig antibodies, activate tonsillar B-cells and induce low levels of B-cell proliferation. In contrast, anti-Bp50 monoclonal antibody along neither activates B-cells nor induces B-cells to proliferate, but together with anti-Bp35 or anti-Ig antibodies, augments B-cell proliferation. In this respect the action of anti-Bp50 antibody resembles the activity of B-cell growth factors (BCGF). As little as 0.05 ug/ml of anti-Bp50 is needed to augment proliferation and, like BCGF, anti-Bp50 is effective even when added 12 to 24 hours after B-cells are activated with anti-Ig or anti-Bp35. Without additional exogenous signals, anti-Bp35 and anti-Bp50 antibodies together induce strong proliferation of purified resting B-cells. These results suggest that the Bp35 and Bp50 surface molecules function in the regulatory control of the B-cell activation and progression through the cell cycle. Because of the significance anti-Bp35 and like molecules have on the effect and action of the ligands of the present invention, Clark et al., 1985, Proc. Natl. Acad. Sci. (USA) 82:1766-1770 is incorporated by reference herein.

Although the activity of anti-Bp50 resembles that of BCGF (low) since both anti-Bp50 and BCGF (low) are costimulatory with the same agents but not with each other and both anti-Bp50 and BCGF (low) affect only activated B-cells and work in a soluble form, the activity of anti-Bp50 can be distinguished from the activity of BCGF (low), since the proliferation of B-cells stimulated with optimal amounts of anti-Bp50 and anti-Bp35 (or anti-Ig) can be augmented further with BCGF (low) and both blood B-cells and certain B-cell lymphomas respond differently to anti-Bp50 versus BCGF. For optimal activity, anti-Bp50 should be added within 12 hours of B-cell activation, whereas BCGF (low) retains optimal activity even when added 24 hours after activations. In addition, Bp50 is expressed on all B-cells while receptors or BCGF (low) are restricted to activated B-cells. Thus anti-Bp50 and BCGF (low) may coordinately regulated B-cell growth, but apparently do so through distinct signals.

In one embodiment of the present invention, the ligands which bind to Bp50 and augment the proliferation of activated B-cells can be used to increase an immune response. For example, these ligands which bind Bp50 can be used as an "adjuvant" to increase an immune response to a vaccine. Alternatively, these ligands can be used to increase the immune response of an immunosuppressed individual.

In another embodiment, the ligands of the invention can be chemically modified so that the

cells to which the ligands bind are killed. Since all B-cells express the Bp50 antigen, this approach would result in suppression of the immune response. For example, a cytotoxic drug linked to a ligand of the present invention can be used *in vivo* to cause immunosuppression in order to cross histocompatibility barriers in transplant patients; alternatively, these modified

5 ligands may be used to control autoimmune diseases. 5

In another embodiment of the present invention, malignancies such as tumor cells that express Bp50 can be treated using a ligand of the invention linked to a chemotherapeutic agent useful in treating such neoplastic disease. These modified ligands can be used *in vivo* to direct the chemotherapeutic agent to any type of malignant cell which expresses the Bp50 antigen includ-

10 ing cells which are not B-cells but which do not express Bp50. When using the ligands of the 10

invention which augment B-cell proliferation, a particular advantage should be realized when treating B-cell malignancies where the chemotherapeutic agent linked to the ligand comprises one that is more effective in killing proliferating cells; in this instance a potentiation of the drug action should be obtained.

15 Alternatively, the ligands of the invention can be used *in vitro* to identify or separate cells 15

which express the Bp50 antigen and/or to assay body fluids for the presence of the Bp50 antigen which may or may not be shed. In addition, the ligands of the invention can be used *in vivo* in order to image cells or tumors which express the Bp50 antigen.

The purified Bp50 antigen of the present invention can be used to make antibodies and to

20 make or design other ligands of the invention. In addition the Bp50 antigen could be used in 20

assays such as diagnostic immunoassays. Moreover, Bp50 itself may be used as a mediator of cell immunity *in vivo* or *in vitro*.

3.1. DEFINITIONS

25 As used herein, the following abbreviations will have the meanings indicated: 25

AO=acridine orange

BCGF=B-cell growth factor

BCGF (high)=a 60 kDa human BCGF

BCGF (low)=a 12 kDa human BCGF

30 Bp35=a 35k Da B-cell specific surface polypeptide (CD20) defined by mAb 1F5 30

Bp50=a 50k Da B-cell specific surface polypeptide defined by mAb G28-5

Fv=the variable region or antigen-combining site of an antibody molecule. This may be any fragment which contains the idiotype of the molecule including but not limited to the Fab, F(ab')₂, Fab', and the like.

35 IF=immunofluorescence 35

Ig=immunoglobulin

IL-1=interleukin 1

IL-2=interleukin 2

kDa=kilodalton

40 mAb=monoclonal antibody 40

SDS-PAGE=sodium dodecyl sulphate-polyacrylamide gel electrophoresis

TPA=12-O-tetradecanoylphorbol-13 acetate

4. DESCRIPTION OF THE FIGURES

45 Figure 1. Expression of Bp50 is restricted to Bp35⁺B-cells. Two-color flow cytometric analy- 45

sis of 50,000 cells was performed as described (Clark, et al., 1985, Proc. Nat. Acad. Sci. USA 82:1766-1770). The data are plotted as cell number versus log of green fluorescence and log of red fluorescence where 4-5 dots represent approximately a doubling of fluorescence. The data are presented to show autofluorescent negative cells. PE (red) -anti-Bp35 (1F5) versus FITC

50 (green) -anti-Bp50 (G28-5) staining shows that all Bp50⁺ cells are also Bp35⁺. 50

Figure 2. Biochemical comparison of Bp50 polypeptide with other B-cell surface antigens.

Immunoprecipitation of Bp50 from surface ¹²⁵I-labeled tonsillar cells was performed as described. Isolated antigens were electrophoreses on 10% SDS polyacrylamide slab gels without reduction. Gels were visualized with autoradiography and intensifying screens. Panel A: lane 1, anti-Bp50

55 (G28-5); lane 2, anti-Bp95 (G28-8); lane 3, sepharose-goat anti-mouse Ig only. Exposure time: 55

4 days. Panel B: lane 1, anti-Bp50 (G28-5); lane 2, anti-Bp45 (BLAST-2); lane 3, anti-Bp39 (G28-1); lane 4, anti-Bp39 (41-H16); lane 5, sepharose-goat anti-mouse Ig only. An exposure time of 2 days was selected so that the bands in lanes 2 to 4 were not overexposed and could be clearly distinguished relative to Bp50. One of three experiments.

60 Figure 3. Two-color immunofluorescence analysis of Bp50 expression. Peripheral blood or 60

tonsillar mononuclear cells were isolated by centrifugation on Ficoll and stained with PE (red)-conjugated G28-5 (anti-Bp50) in combination with fluorescein (green)-conjugated reference antibodies, including 2C3 (anti-IgM); 1F5 (anti-Bp35); HB10a (anti-DR); and 9.6 (anti-CD2, E receptor). Cells were analyzed with a FACS IV fitted with four decade log amplifiers in both red and

65 green dimensions. Forward and right angle light scatter was used to gate out monocytes. 65

Unstained cells are positioned at the back of the grid; red fluorescence is to the right and green fluorescence is to the left.

Figure 4. Dose response curves for augmentation of proliferation of dense tonsillar E- B-cells by anti-Bp50 antibodies as indicated: Media only; anti-Bp50 only anti-Bp35 (5ug/ml) only; BCGF only; anti-Bp35 plus BCGF; anti-Bp35 plus graded doses of anti-Bp50. Mean proliferation $\pm$ standard error of quadruplicate samples was measured on day 3. 5

Figure 5. Anti-Bp50 mAb are most effective at augmenting proliferation if added after a B-cell activation signal. Dense tonsillar E- B-cells were incubated for 4 days with media only, anti-Bp50 (0.5 ug/ml) added at different times after incubation, anti-Bp35 (5 ug/ml) added at different times after incubation; anti-Bp50 kept constant to which anti-Bp35 was added later 10 different times; anti-Bp35 kept constant to which anti-Bp50 was added to cultures at different times. During the last 10 hr ^3H -thymidine was added and its incorporation was measured. 10

Figure 6. Comparison of the ability of anti-Bp35 and anti-Bp50 to induce resting tonsillar B-cells to leave the G_0 stage of the cell cycle. Day 3 post treatment media only (—), anti-Bp35 only (—); and Ig only (....), A, no additional additives; B, anti-Bp50 (0.5 ug/ml) added to each group; C, 5% BCGF added to each group. Data is plotted as relative cell number versus log of AO red fluorescence (RNA). 15

Figure 7. Kinetics of B-cell proliferation after stimulation with anti-Bp50 versus BCGF. Dense tonsillar E-B-cells were stimulated with media along; 10% BCGF only; anti-Bp35 only; anti-Bp50 only; anti-Bp35+10% BCGF; anti-Bp35+anti-Bp50; and anti-Bp35-anti-Bp50+10% BCGF. Proliferation was measured on the days indicated by an 18-hour pulse of ^3H thymidine. Proliferation was measured in quadruplicate and standard errors are shown. One of three experiments. 20

Figure 8. Times after anti-Bp35 stimulation when anti-Bp50 (A) or BCGF (B) optimally augment proliferation. Dense tonsillar E- B-cells were stimulated as shown and proliferation was measured by an 18 hour pulse of ^3H thymidine on day 3. Media; anti-Bp35 only added at times indicated; anti-Bp50 or BCGF only; anti-Bp35 added at start of culture followed by addition of anti-Bp50 or BCGF at times indicated; anti-Bp50 or BCGF added at start of culture followed by anti-Bp35. One of two experiments. Proliferation was measured in quadruplicate and standard errors are shown. Doses used: anti-Bp35, 5 ug/ml; anti-Bp50, 0.2 ug/ml; BCGF (low) 5%. Concentrations used were as follows: anti-Bp35, 5 ug/ml; anti-Bp50, 0.2 ug/ml; BCGF, 5%. 30

Figure 9. Anti-Bp50 and BCGF have additive effects on B-cell proliferation. Dense tonsillar E-B-cells were stimulated with graded doses of BCGF (low) together with anti-Bp50 only; anti-Bp35 only; anti-Ig-beads only; anti-Bp35+anti-Bp50; or anti-Bp50+anti-Ig. Proliferation was measured on day 3 after stimulation with an 18-hour pulse of ^3H thymidine. Proliferation was measured in quadruplicate and standard errors are shown. One of four experiments. Doses used 10^6 cells: anti-Bp35, 5 ug/ml; anti-Bp50, 0.2 ug/ml; anti-Ig-beads, 50 ug/ml. 35

Figure 10. Comparative effects of anti-Bp50 and BCGF on normal and malignant B-cells. Peripheral blood E- B-cells (A) or dense tonsillar E- B-cells (C) were stimulated with or without TPA (75 ng/ml) in the presence of 10% BCGF or 1 ug/ml anti-Bp50. Two separate B-cell lymphomas (panels B and D) were stimulated in the same way. Proliferation was measured on day 3 by incorporation of ^3H thymidine during a 12-hour pulse. Proliferation was measured in quadruplicate and standard errors are shown. 40

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to ligands which (a) bind to Bp50, a 50kDa B-cell specific surface polypeptide, and (b) augment the proliferation of activated B-cells. The invention is also directed to the Bp50 antigen itself, which is defined by mAb G28-5 and functions in B-cell proliferation. In addition, the invention is directed to ligands which bind to Bp50 but do not demonstrate a biological effect or function such as augmentation of proliferation of activated B-cells. 50

The ligands of the present invention include antibody molecules, monoclonal antibody molecules and fragments of these antibody molecules which contain the antigen combining site that binds to the Bp50 receptor including chemically modified antibodies and fragments; such fragments include but are not limited to the Fv, Fab, F(ab')₂, Fab' and the like. In addition, the ligands of the present invention comprise lymphokines, which bind to the Bp50 receptor. These may include but are not limited to BCGFs as well as chemically modified lymphokines and the like. The ligands of the invention can be used in their modified or unmodified forms to modulate and regulate immune responses and in the therapy of malignancies which express the Bp50 antigen. These uses are discussed in more detail in Section 5.4 below. 55

Where the ligand is a monoclonal antibody, or a fragment thereof, the monoclonal antibody can be prepared against Bp50 using any technique which provides for the production of antibody molecules by continuous cell lines in culture. For example, the hybridoma technique originally developed by Kohler and Milstein (1975, Nature 256:495-497) as well as other techniques which have more recently become available, such as the human B-cell hybridoma technique (Kozbor et al., 1983), Immunology Today 4:72) and the EBV-hybridoma technique to produce 60 65

human monoclonal antibodies (Cole et al., *Monoclonal Antibodies and Cancer Therapy*, Alan R. Liss, Inc., pp. 77-96) and the like are within the scope of the present invention.

Antibody fragments which contain the idiotype of the molecule could be generated by known techniques. For example, such fragments include but are not limited to: the $F(ab')_2$ fragment which can be generated by treating the antibody molecule with pepsin; the Fab' fragments which can be generated by reducing the disulfide bridges of the $F(ab')_2$ fragment; the $F(ab')_2$ fragment which can be generated by treating the antibody molecule with papain; and the 2Fab or Fab fragments which can be generated by treating the antibody molecule with papain and a reducing agent to reduce the disulfide bridges.

Where the ligand that binds Bp50 is a lymphokine, the lymphokine may be obtained from natural sources or if its amino acid sequence is known or deduced the lymphokine can be synthesized via chemical synthetic methods. Alternatively, if the gene sequence of the lymphokine is known, recombinant DNA techniques may be utilized to clone the gene in an expression vector which provides for transcription and translation of the gene sequence in an appropriate host cell.

Depending upon its intended use, the ligand or appropriate fragments of the ligand may be chemically modified by the attachment of any of a variety of compounds to the ligand using coupling techniques known in the art. Such techniques may include but are not limited to the use of carbodiimide, cyanogen bromide, bifunctional reagents such as glutaraldehyde, N-succinimidyl 3-(2-pyridyldithio) propionate (SPDP), Schiff base reactions, attachment to sulfhydryl moieties, the use of sodium isothiocyanate, or enzymatic linkage, to name but a few. Where a radioisotope is to be attached to the ligand this may also be accomplished via enzymatic means, oxidative substitution, chelation etc. For a review of the chemical reagents which can be used for protein modification see, Lundblad and Noyes, *Chemical Reagents for Protein Modification*, Volume II, CRC Press, Inc., Boca Raton, Florida, Ch. 5, pp. 123-139, 1984.

The chemical linkage or coupling of a compound to the ligand could be directed to a site on the ligand that does not participate in binding to Bp50. This could be accomplished by protecting the binding site of the ligand prior to performing the coupling reaction. For example, the ligand can first be bound to Bp50 in order to protect the Bp50 binding site, then the coupling reaction can be accomplished to link the desired compound to available reactive sites on the ligand-Bp50 complex. Once the coupling reaction is complete, the complex can be disrupted thereby generating a modified ligand to which the desired compound is attached so that the Bp50 binding site of the molecule is minimally affected. Where the ligand comprises a monoclonal antibody such as G28-5, in which the Fc domain of the molecule is not required for the ligand to exert its effect (see Section 5.3.3. infra) it may be advantageous to direct the coupling of the desired compounds to the Fc domain of the molecule.

The subsections below describe the new, 50-kDa B-cell surface marker, Bp50, which apparently functions in B-cell proliferation as well as ligands which bind to the new 50kDa receptor, and their uses. As an example of the ligands of the present invention a monoclonal antibody which defines Bp50 and its $F(ab')_2$ fragments are also described which, like BCGF, augments B-cell proliferation. Unlike anti-Bp35 mAb, which can induce resting B-cells in G_0 to enter G_1 , anti-Bp50 mAb does not activate resting B-cells. Anti-Bp35 and anti-Bp50 mAb together, without any additional exogenous signals, induce strong activation and proliferation of purified B-cells.

The experiments described below also demonstrate that anti-Bp50 activity resembles BCGF activity but that anti-Bp50 is distinct from one BCGF since anti-Bp50 and low molecular weight BCGF are clearly additive and act differently on various B-cell subsets or malignancies. Bp50 may be a receptor for a distinct BCGF or for a transmembrane signal that modulates BCGF production or BCGF receptor expression.

5.1 METHODS USED TO CHARACTERIZE THE Bp50 RECEPTOR

Cell preparations. Mononuclear cells were isolated from normal or leukemic heparanized peripheral blood by Ficoll-Hypaque gradients (Pharmacia, Piscataway, NJ). Mononuclear cells were obtained from tonsillar tissues as described (Clark, et al., 1985, *Proc. Nat. Acad. Sci. USA* 82:1766-1770). T cells were depleted with AET-treated sheep erythrocyte rosetting and Ficoll-Hypaque gradient separation. In some experiments blood B-cells were enriched by isolating nylon wool adherent cells. Monocytes were removed by incubation on plastic petri dishes one or two times at 37°C for 45 minutes unless otherwise stated. Buoyant or dense tonsillar B-cell fractions were isolated by Percoll step gradients as described (Clark, et al., 1985, *Proc. Nat. Acad. Sci. USA* 82:1766-1770). Dense tonsillar B-cell preparations consistently had greater than 95% slg+Bp35+ cells. Blood B-cell-enriched preparations had 60-85% slg+ cells. B-cell lymphoma cells were isolated by gently teasing lymphoma cells into medium followed by Ficoll-Hypaque gradient centrifugation.

Monoclonal antibodies. The G28-5 antibody to Bp50 was generated by immunizing BALB/c mice with human E- tonsillar lymphocytes and fusing immune spleen cells with the NS-1 myeloma (Kohler, et al., 1975, *Nature* 256:495-497; Ledbetter, et al., 1979, *Immunol. Rev.*

- 47:63–82). Hybrid cell cultures secreting antibody reactive with tonsillar B-cells and not with T cells were identified by the use of indirect immunofluorescence (IF) and analysis with a FACS IV cell sorter; cultures with antibody giving histogram patterns similar to known mAb to pan B-cell markers (e.g., Bp35) were cloned and selected for further study. The G28–5 clone produced an IgG₁ mAb that reacted only with normal or malignant B-cells or B-cell lines. Other mAb used in this study have been described in detail (Clark, et al., 1985, Proc. Nat. Acad. Sci. USA 82:1766–1770; Clark et al., 1986, Human Immunol. 16:100; Ledbetter, et al., 1986, Human Immunol. 15:30–44; Ledbetter, et al., 1985, in *Perspectives in Immunogenetics and Histocompatibility*, ASHI, New York, 6, pp. 325–340). These include 1F5 (IgG_{2a}) anti-Bp35, HB10a (IgG_{2a}), anti-HLA-DR, 2C3 (IgG₁) anti-u chain, G19–4 (IgG₁) anti-CD3, FC-2 (IgG_{2a}) anti-Fc receptor CD16, and 9.6 (IgG_{2a}) anti-CD2 (E receptor) provided by Dr. Paul Martin (Martin, et al., 1983, J. Immunol. 131:180). The IgG₁ mAbs were purified by precipitation using 45% or 50% saturated ammonium sulfate and DEAE Sephacryl column chromatography, and the IgG_{2a} mAbs were purified by the use of protein A Sepharose columns. The F(ab')₂ fragments of G28–5 were prepared by the method of Parham (Parham, et al., 1983, J. Immunol. 131:2895) purified on a 2-meter long sephacryl S200 column, and assayed for purity by SDS-PAGE (Ledbetter, et al., 1985, J. Immunol. 135:1819). The 2C3 mAb to u-chains was conjugated to Sepharose 4B beads (Pharmacia Fine Chemicals, Uppsala, Sweden) using cyanogen bromide coupling.
- Fluorescein and phycoerythrin conjugations.** Purified mAb were either directly conjugated with fluorescein using fluorescein-isothiocyanate (FITC; Molecular Probes) (green) by the method of Goding (Goding, et al., 1976, J. Immunol. Meth. 13:215–226), or conjugated to R-phycoerythrin (PE) (red) by using SPDP (Pharmacia) with a method we have detailed in Ledbetter, et al., 1985, in *Perspectives in Immunogenetics and Histocompatibility*, ASHI, New York, 6, 119–129. Lymphoid cells were incubated in round-bottom microtiter plates for 30 minutes with an appropriate dilution of green and/or red mAb, washed twice, and then analyzed on a FACS IV cell sorter.
- Two-color immunofluorescence.** Two-color studies were done with a fluorescence-activated cell sorter (FACS IV; Becton-Dickinson, Mountain View, CA) by using a 560-nm dichroic mirror to split the beam and a 580 long-pass filter and a 540 short-pass filter (Ditric Optics, Hudson, MA) in front of the red and green photomultiplier tubes, respectively. In addition, a two-color compensator (T. Nozaki, Stanford University) was used to correct for minor spillover of green and red signals. For each two-color stain, data from 40,000 cells were collected and stored on floppy disks. Data are presented as cell number (vertical) versus log green fluorescence versus log red fluorescence on a 64×64 dot grid. Approximately 4.5 dots represents a doubling of fluorescence. Unstained cells are positioned at the back corner of the grid; red fluorescence is to the right and green fluorescence is to the left. Our flow cytometry system for two-color IF with fluorescein and phycoerythrin is described in more detail (Ledbetter, et al., 1985, in *Perspectives in Immunogenetics and Histocompatibility*, ASHI, New York, 6, 119–129 and 325–340).
- Cell culture.** Blood or tonsillar lymphoid cells were cultured at 5–10×10⁵ml in quadruplicate in 96-well microtiter plates containing 200 ul RPMI-1640 medium supplemented with 15% fetal bovine serum, antibiotics, glutamine, and pyruvate (R15). After 1 to 7 days, cells were pulsed with 0.5 uCi of ³H thymidine per well (New England Nuclear, 6.7 Ci/mmol; 1 Ci=37) for 18 hours. Cells were then harvested onto glass-fiber filters with a cell harvester, and radioactivity was measured in a scintillation counter. In some experiments, antibodies or factors were added at various times after the start of cultures; proliferation in these experiments was measured on day 3.
- Costimulatory factors.** Purified BCGF was purchased from Cytokine Technology (Buffalo, New York) and contained no detectable IL-1, IL-2, or interferon activity. This BCGF was prepared by the method of Maizel and coworkers (Maizel, et al., 1982, Proc. Nat. Acad. Sci. USA 79:5998), who have shown that the major BCGF activity in this material resides in a 12-kDa species, hereinafter referred to as "BCGF (low)" (Mehta, et al., 1985, J. Immunol. 135:3298). The purification steps included preparative scale DEAE affinity chromatography followed by hydroxylapatite column chromatography. IL-1 purified to homogeneity was the generous gift of Dr. Steven Dower (Dower, et al., 1985, J. Exp. Med. 162:501). Recombinant IL-2 was kindly provided by Cetus Corporation. TPA (12-O-tetradecanoyl phorbol 13-acetate) was purchased from Sigma.
- Detection of cell activation.** Changes in cell volume induced by mAb and/or factors were measured using a cell sorter and forward angle light-scatter. Cell cycle changes in cellular RNA and DNA levels were measured by staining activated cells with acridine orange and measuring relative cellular RNA (red) and DNA (green) content with a cell sorter by the method of Darzynkiewicz et al. (Darzynkiewicz, et al., 1980, Proc. Nat. Acad. Sci. USA 77:6697–6702). Changes in relative levels of cell surface antigens were monitored by use of mAb directly conjugated with fluorescein and then quantitated by direct IF fluorescence levels with an Epics V cell sorter.
- Biochemical characterization of Bp50.** Immunoprecipitation of Bp50 from surface ¹²⁵I-labeled tonsillar cells was performed as described (Ledbetter, et al., 1985, J. Immunol. 134:4250–4254). Isolated antigens were electrophoresed on 10% SDS polyacrylamide slab gels without reduction. Gels were visualized using autoradiography at –70°C and Cronex lightening

plus intensifying screens (Dupont).

5.2. CHARACTERIZATION OF THE Bp50 RECEPTOR

The subsections below describe the results of the experiments conducted using the methods described above.

5.2.1. IDENTIFICATION OF A B-CELL SPECIFIC 50 KDA CELL SURFACE MARKER, Bp50.

A mAb to Bp50 was raised by immunizing BALB/c mice with human tonsillar lymphocytes and fusing immune spleen cells with the NS-1 myeloma. One clone, G28-5, produced an IgG₁ mAb that did not contain the NS-1 light chain. Upon scrutiny by IF analysis, G28-5 was found to react only with normal or malignant B-cells or B-cell lines. A comprehensive screening of normal tissues by established methods (Clark, et al., 1985, Proc. Nat. Acad. Sci. USA 82:1766-1770; Ledbetter et al., 1986, Human Immunol. 15:30-44; Ledbetter, 1985, in *Perspectives in Immunogenetics and Histocompatibility*, ASHL, New York, 6, pp. 325-340) revealed that the G28-5 antibody reacts with E rosette negative (Er-) cells from blood or tonsils but not with nylon wool nonadherent T cells, PHA-induced T-cell blasts, or with blood granulocytes, monocytes, red cells, or platelets. It reacted strongly with all seven B lymphoblastoid cell lines tested and with three Burkitt's lymphoma lines (Raji, Daudi, Namalwa), but not with four T cell lines (CEM, HSB-2, JURKAT, and HPB-ALL). All chronic lymphocytic leukemias tested (3/3) and 90% (9/10) of B lymphomas tested expressed the Bp50 marker while only 28% (2/7) of non T, non B CALLA⁺ acute lymphocytic leukemias expressed Bp50.

The restricted distribution of Bp50 on normal tissues was further confirmed by quantitative two-color immunofluorescence (two color IF) analyses. Using an R-phycoerythrin (PE)-conjugated antibody (red) to the pan B-cell antigen Bp35 (B1, CD20) and fluorescein-conjugated anti-Bp50 antibody (green), we found that Bp50 was expressed only on Bp35⁺ B-cells (Fig. 1) in blood or tonsils. Blood B-cells consistently expressed somewhat lower levels of Bp50 than tonsillar B-cells; this is similar to HLA-DR expression, (Ledbetter et al., 1986, Human Immunol. 15:30-44) and to gp54 expression (Wang, et al., 1979, J. Exp. Med. 149:1424-1433) which are also lower on blood B-cells. Bp50 was expressed at similar levels on tonsillar B-cell subpopulations separated on Percoll gradients into buoyant and dense fractions. Using our PE-conjugated mAb to the T cell marker, CD3(T3), and NK cell-associated marker, CD16(Fc receptor) (Ledbetter, et al., 1979, Immunol. Rev. 47:63-82), we found that Bp50 is not expressed on T cells or NK cells. Using two-color IF, we also found that CD3⁺ PHA blasts that expressed high levels of IL-2 receptors did not express Bp50.

The G28-5 antibody reacted with a single polypeptide on tonsillar lymphocytes that migrated at approximately 50 Kd under non-reducing conditions (Fig. 2A). This molecule is larger than previously reported B-cell markers in the same molecular weight range such as Bp39 or Bp45 (Zipf, et al., 1983, J. Immunol. 131:3064-3072; Kitner, et al., 1981, Nature 294, 458-460; Clark, et al., 1986, in *Leukocyte Typing II*, eds. Reinherz, et al., Springer Verlag, Berlin, Chap. 12 Vol. 2, 155-167; Slovin, et al., 1982, Proc. Nat. Acad. Sci. USA 79:2649-2653; Thorley-Lawson, et al., 1985, J. Immunol. 134:3007-3012, and Fig. 2B). The exposure time for this gel was selected so that the molecular weights of the other B-cell markers could be readily compared with Bp50. The Bp39 marker, unlike Bp50, is expressed on granulocytes and Bp45, unlike Bp50, is restricted to B-cell blasts. Antibodies to Bp39 (41-H16) and Bp45 (MNM6, Blast-1, Blast-2) made available through an international workshop (Clark, et al., 1986, in *Leukocyte Typing II*, eds. Reinherz, et al., Springer Verlag, Berlin, Chap. 12 Vol. 2, 155-167) did not block the binding of fluoresceinated anti-Bp50 antibodies to B-cells. Thus, based on tissue distribution, biochemical analysis, and blocking studies, the G28-5 monoclonal antibody recognizes a 50-Kd structure distinct from other known B-cell antigens.

5.2.2. EXPRESSION OF Bp50 IS RESTRICTED TO B-CELLS

Both hematopoietic tissue and cell-line distribution studies and detailed two-color flow cytometric analyses revealed that Bp50 is expressed only on B lymphocytes. As illustrated in Fig. 3, Bp50 is expressed on a small subset of blood lymphocytes and on a large population of tonsillar lymphocytes. Virtually all Bp50⁺ cells in both blood and tonsils also expressed Bp35 and HLA-DR, but did not express the CD2 (Fig. 1) or CD3, T-cell molecules or the IgG Fc receptors that are found on NK cells. Furthermore, ConA-activated CD3⁺ T-cell blasts expressed IL-2 receptors but did not express Bp50.

Two-color flow cytometric analyses allow the quantitative measurement of the density relationship between two surface antigens. We previously showed that the dense, resting B-cells in the mantle zone of secondary follicles express IgM and low levels of Bp35, whereas the buoyant, activated B-cells in the germinal center are IgM-negative and express elevated levels of Bp35 (Ledbetter, et al., Human Immunol. 15:30). Fig. 3 shows that both IgM-positive and IgM-negative B-cell subsets expressed Bp50 in equal amounts, indicating that Bp50 is expressed on both resting B-cells and B-cells activated *in vivo*.

5.3. AUGMENTATION OF B-CELL PROLIFERATION WITH ANTI-Bp50 ANTIBODY

As previously explained, B-cells can be activated with low doses of anti-u chain specific antibodies. We recently found that the B-cell-specific marker Bp35 (Bl), a 35-kDa polypeptide, may also function in early B-cell activation: the 1F5 mAb to Bp35, like low doses of anti-u antibody, activates B-cells to increase in cell volume and RNA content and to become responsive to BCGF (Clark, et al., 1985, Proc. Nat. Acad. Sci. USA 82:1766-1770; Gollay, et al., 1985, J. Immunol. 135:3795-3801). Therefore, it was of interest to compare the effect of anti-Bp50 mAb in the proliferation of untreated B-cells or B-cells activated with either anti-Bp35 or anti-u antibodies (Table 1). Anti-Bp35 in solution or anti-u antibodies attached to Sepharose beads, under appropriate conditions alone, could stimulate some B-cell proliferation (Table 1, line 1); in contrast, anti-Bp50 antibodies alone did not stimulate proliferation (Table 1, line 2). However, anti-Bp50 mAb augmented proliferation considerably when cultured with anti-u beads or with anti-Bp35. In this respect anti-Bp50 resembled BCGF (Table 1, line 3). Thus, it was important to determine whether anti-Bp50 and BCGF together could induce B-cell proliferation. As illustrated in Table 1, line 4, anti-Bp50 and BCGF together induced no proliferation, but did augment proliferation of either anti-u or anti-Bp35 activated cells somewhat more than either stimulant alone. BCGF over a three-log range, when used with anti-Bp50 without other signals, had no effect on proliferation of dense B-cells even when anti-Bp50 was used at doses ranging from 0.1 to 10 ug/ml.

Table 1

Augmentation of Anti-Ig or Anti-Bp35
Induced B Cell Proliferation With Anti-Bp50 Antibodies

Mean Proliferation $\pm$ S.E. of B Cells Cultured With:

Line	Co-stimulant	Media	Anti-u-beads	Anti-Bp35
1	None	1,212 $\pm$ 547	10,219 $\pm$ 462	5,539 $\pm$ 308
2	Anti-Bp50	719 $\pm$ 718	38,792 $\pm$ 1,329	25,465 $\pm$ 616
3	BCGF	456 $\pm$ 217	14,217 $\pm$ 445	9,443 $\pm$ 343
4	Anti-Bp50 + BCGF	1,456 $\pm$ 126	54,393 $\pm$ 2,537	46,488 $\pm$ 3,387

Proliferation of dense Er- tonsillar B-cells (95% surface IgM⁺ cells) was measured on day 3 as described. Briefly, 2 x 10⁵ cells/200 ul well were cultured in quadruplicate for 48 hrs with RPMI 1640 medium containing 15% fetal bovine serum plus additives without antibody or with either 2C3 monoclonal antibody to u chains coupled to sepharose beads ("anti-u beads," 50 ug/ml) or free 1F5 anti-Bp35 antibody (5 ug/ml). Cultures containing media, "anti-u beads," or anti-Bp35 were cultured alone or with BCGF (5% final concentration, Cytokine Technology, Buffalo, New York; has no detectable IL-1 or IL-2 activity), with anti-Bp50 (1:1000 dilution of ascites) as co-stimulants. After 40 hrs cells were pulsed with ³H-thymidine, and counts incorporated were measured after 18 hrs.

5.3.1. ANTI-Bp50 mAb AUGMENTS PROLIFERATION ONLY AFTER B-CELLS ARE ACTIVATED BY ANTI-Bp35 OR ANTI-u-ANTIBODIES

The results in Table 1 suggests that anti-Bp50 mAb could not induce proliferation by itself. As shown in Fig. 4, doses of anti-Bp50 ranging from 0.05 ug to 2.0 ug/ml had no effect on ³H-thymidine uptake. However, in the presence of optimal levels of anti-Bp35 mAb, as little as 0.1

to 0.5 ug/ml of anti-Bp50 antibodies augmented proliferation substantially. As much as 50,000 to 70,000 cpm were detectable at the optimal time of proliferation when highly purified B-cells were cultured only with anti-Bp35 plus anti-Bp50. A consistent observation was that higher doses of anti-Bp50 (greater than 2–5 ug/ml) were less effective than doses in the 100–200 ng range.

These results suggested that anti-Bp50 may function only after B-cells are activated by other signals. Data shown in Fig. 5 suggest that this is indeed the case. If B-cells were first activated with anti-Bp35, anti-Bp50 could be added as late as 24–48 hours later and still augment proliferation at day 4. In contrast, when cells were first treated with anti-Bp50, anti-Bp35 was effective only if added within a few hours after the start of the cultures. Similar results were found when anti-u rather than anti-Bp35 was used.

5.3.2. ANTI-Bp50 mAb DO NOT ACTIVATE B-CELLS OUT OF G_0 BUT DO INDUCE ACTIVATED B-CELLS TO PROGRESS THROUGH THE CELL CYCLE

Previously, we have found that anti-Bp35, like low doses of anti-u antibodies, induce resting tonsillar B-cells in G_0 to enlarge (Clark, et al., 1986, *Leukocyte Typing II*, eds., Reinherz, et al., Springer Verlag, Berlin, Vol. 2, 455–462) and to enter the G_1 phase of the cell cycle (Gollay, et al., 1985, *J. Immunol.* 135:3795–3801). Thus, it was of interest to compare the ability of anti-Bp50 mAb to anti-Bp35 mAb for their effects on B-cell activation. As shown in Fig. 6A, unstimulated dense tonsillar B-cells even after 3 to 4 days in culture had a uniform RNA profile characteristic of cells in G_0 (Darzynkiewicz, 1980, *Proc. Nat. Acad. Sci. USA* 77:6697–6702). However, about 15–30% of cells stimulated with anti-Bp35 or anti-u had increased RNA content indicative of entry into G_1 . In contrast, neither anti-Bp50 (Fig. 6B) nor BCGF (Fig. 6C) alone induced significant numbers of B-cells to enter G_1 . For instance, 2 days after activation, anti-Bp35 and anti-Ig mAb induced respectively 13.5% and 20.9% of tonsillar cells to enter G_1 , whereas cells treated with only anti-Bp50 (2.7%) or BCGF (3.2%) remained at media control levels (2.2%). However, when either anti-Bp50 or BCGF were added together with anti-Bp35 or anti-u antibodies, the proportion of cells entering G_1 increased dramatically. Similarly, anti-Bp50 and BCGF alone did not induce B-cells to enter S phase (Table 2), but together with either anti-Bp35 or anti-u did increase the number of S phase cells two- to threefold.

Table 2

Effect of Anti-Bp50 and BCGF on
Cell Cycle Progression in Tonsillar Lymphocytes

Competence Signal	Progression Signal	G ₀	% Cells G ₁	S/G ₂ /M
media	none	89.9	7.1	2.5
anti-Bp35	"	80.4	14.5	3.7
anti-Ig	"	65.6	27.6	5.7
media	anti-Bp50	83.6	12.0	3.3
anti-Bp35	"	54.1	35.5	9.7
anti-Ig	"	43.6	36.2	16.2
media	BCGF	85.4	11.7	2.2
anti-Bp35	"	56.6	32.6	11.6
anti-Ig	"	48.4	36.1	14.1
Percentage of cells in G ₀ , G ₁ , or S and G ₂ determined with the use of the acridine Orange-staining procedure (Darzynkiewicz, et al., 1980 Proc. Nat. Acad. Sci. USA 77:6697-6702); 1 x 10 ⁶ dense tonsillar lymphocytes with anti-Bp35 (5 ug/ml), anti-u on beads (50 ug/ml), anti-Bp50 (0.4 ug/ml), BCGF (5%) or combinations as shown.				

40

5.3.3. OPTIMAL CONDITIONS FOR AUGMENTING B-CELL PROLIFERATION WITH ANTI-Bp50 ANTIBODIES

Antibodies to Bp50 by themselves have little or no detectable effect on dense resting B-cells (Table 3). However, in the presence of agents that can activate B-cells, such as anti-Ig, anti-Bp35 and TPA, anti-Bp50 mAb clearly augmented proliferation. Anti-Bp50 did not costimulate with several interleukins, including purified IL-1, recombinant IL-2 and BCGF (low). A comparison of the effects of anti-Bp50 with those of BCGF (low) showed that the same agents that were costimulatory with anti-Bp50 were also costimulatory with BCGF (low) (Table 3). Of particular interest was the finding that together BCGF and anti-Bp50 still were not costimulatory for resting cells.

Table 3

Augmentation of B-Cell Proliferation with
Anti-Bp50 Antibodies or B-Cell Growth Factor

Mean Proliferation + S.E. of B-Cells Cultured with:			
Co-stimulant	Media	Anti-Bp50 (200 ng/ml)	BCGF (5%)
none	96 ± 1	267 ± 15	285 ± 74
anti-Ig	5,833 ± 391	41,634 ± 2,103	25,094 ± 61
anti-Bp35 (5 ug/ml)	457 ± 45	8,143 ± 280	1,733 ± 32
TPA (2 ng/ml)	7,361 ± 537	21,163 ± 871	13,064 ± 1,030
IL-1 (10 U/ml)	264 ± 2	308 ± 23	221 ± 8
IL-2 (100 U/ml)	204 ± 34	350 ± 7	220 ± 11
BCGF (5%)	220 ± 7	851 ± 28	270 ± 18
Dense Er- tonsillar B-cells (greater than 95% sIgM ⁺ cells) cultured for 48 hr at 2 x 10 ⁵ cells/well followed by 24 hr pulse with ³ H-thymidine before counting.			

The kinetics of proliferation augmented by anti-Bp50 is shown in Fig. 7. The peak of proliferation occurred at day 4 and then waned whether or not cells were activated with anti-Bp35 or other activators such as anti-Ig or TPA. The kinetics of proliferation augmented by BCGF or by anti-Bp50 were similar.

As little as 0.05 ug of anti-Bp50 antibodies augmented proliferation. An optimal dose of 0.3 ug/ml was used in subsequent studies. A consistent observation was that when using whole antibody molecules, higher doses of anti-Bp50 (greater than 2–5 ug/ml) were less effective than doses in the 0.1–0.5 ug/ml range.

Human B-cells are exquisitely sensitive to inhibitory effects mediated by the Fc receptors of antibodies binding to surface Ig (Parker, 1980, Immunol. Rev. 52:115; Bijsterbosch, et al., 1985, J. Exp. Med. 162:1825). Thus, it was important to compare the efficacy of whole anti-Bp50 mAb with that of anti-Bp50 F(ab')₂ fragments. Over a 100-fold dose range F(ab')₂ fragments were clearly as effective as, or more effective than, whole antibody at augmenting B-cell proliferation (Table 4). Thus, the Fc domain of anti-Bp50 mAb is not required for anti-Bp50 to exert its effect and, if anything, may be inhibitory. In other words, anti-Bp50, like BCGF, apparently can act as a soluble mediator without the aid of Fc receptor-mediated accessory cell function.

5

Table 4

5

The Fc Domain of Anti-Bp50 Antibodies
is Not Required for Augmenting B-Cell Proliferation

10

10

		Mean Proliferation of B Cells Cultured with:		
Dose				
Anti-Bp50	(ug/ml)	Media	Anti-Bp35	
none	--	295 $\pm$ 16	269 $\pm$ 27	
20 whole Ab	0.125	278 $\pm$ 32	5,140 $\pm$ 20	20
	1.25	275 $\pm$ 24	4,686 $\pm$ 342	
	12.5	163 $\pm$ 15	3,852 $\pm$ 203	
25 F(ab') ₂	0.125	594 $\pm$ 21	10,635 $\pm$ 449	25
	1.25	531 $\pm$ 3	10,893 $\pm$ 575	
	12.5	279 $\pm$ 8	9,411 $\pm$ 870	
Cell culture conditions were as described in Table 3.				

30

30

35

35

5.3.4. DIFFERENCES BETWEEN ANTI-Bp50 AND BCGF (LOW) ACTIVITY

Anti-Bp50 and BCGF (low) had a similar effect on B-cells and were costimulatory with the same agents (Table 3). However, several lines of evidence indicate that anti-Bp50 and the BCGF used in this study apparently operate through different signals. First, Bp50 molecules, unlike BCGF (low) receptors (Bijsterbosch, et al., 1985, J. Exp. Med. 162:1825), are expressed on resting blood B-cells (Fig. 3). Second, although both anti-Bp50 and BCGF (low) function most effectively when added after anti-Bp35 or anti-Ig, anti-Bp50 clearly was optimally effective when added 12 hours after cultures began (Fig. 8A). In contrast, BCGF (low) could be added as long as 24 hours after start of cultures and still optimally augment proliferation (Fig. 8B). These kinetic experiments, which are modeled after the approach of Howard and Paul (1983, Ann. Rev. Immunol. 1:307), suggest that a Bp50-dependent signal may normally exert its effect before BCGF.

Both anti-Bp50 and BCGF (low) augmented proliferation of B-cells activated with anti-Bp35 or anti-Ig (Table 3). However, the effect of anti-Bp50 and BCGF (low) were additive in many experiments (Fig. 7). Fig. 9 shows a titration of BCGF (low) in an experiment where anti-Bp50 was used as its optimal concentration (0.2 ug/ml). BCGF (low) could further augment proliferation of resting B-cells in the presence of anti-Bp50 after activation by either anti-Ig or by anti-Bp35. Optimal concentration of BCGF (low) were 5–10%, while 25% was inhibitory. Thus, when anti-Bp50 and BCGF (low) were both used at their optimal concentrations, they still showed additive effects on B-cell proliferation.

Finally, both normal and malignant B-cell subsets differed in their responses to anti-Bp50 and to BCGF (low). For example, some blood B-cells responded to BCGF (low) but did not respond to anti-Bp50 (Table 5). An additional activation signal such as anti-Bp35 (Table 5) or TPA (Fig. 10) was consistently necessary to allow blood B-cells to respond to anti-Bp50. While dense tonsillar B-cells generally did not respond to either BCGF or anti-Bp50, buoyant B-cells did respond (Table 5). B-cell malignancies also differed in their responsiveness to anti-Bp50 versus BCGF. For example, some B-cell lymphomas responded to TPA plus BCGF (low) but not to TPA plus G28–5 anti-Bp50 (Fig. 10B and D). In contrast, dense tonsillar B-cells and peripheral blood B-cells responded to TPA plus either BCGF (low) or anti-Bp50 (Fig. 10A and C).

65

65

Table 5.
B-Cell Subsets Differ in Their Responsiveness to Anti-Bp50 or BCGF

Stimulation	Mean Proliferation ($\pm$ S.E.M.) of Lymphocytes From				
	Blood			Tonsils	
	Exp 1	Exp 2	Exp 3	Dense	Buoyant
none	527 $\pm$ 70	659 $\pm$ 133	906 $\pm$ 106	385 $\pm$ 43	387 $\pm$ 12
BCGF (5%)	13,918 $\pm$ 1,082	37,594 $\pm$ 2,023	3,347 $\pm$ 174	332 $\pm$ 33	1,451 $\pm$ 57
anti-Bp50 (0.5 ug/ml)	519 $\pm$ 28	1,013 $\pm$ 81	1,151 $\pm$ 28	472 $\pm$ 8	1,543 $\pm$ 20
anti-Bp35 (5 ug/ml)	554 $\pm$ 90	645 $\pm$ 89	665 $\pm$ 115	2,415 $\pm$ 80	1,129 $\pm$ 68
anti-Bp50 + anti-Bp35	--	12,274 $\pm$ 546	15,667 $\pm$ 333	36,589 $\pm$ 1,335	4,843 $\pm$ 136
anti-Bp50 + BCGF	--	--	3,943 $\pm$ 115	1,342 $\pm$ 19	2,899 $\pm$ 91

Cell culture conditions as described in Table I. Blood Nylon wool adherent lymphocytes (B cells plus monocytes) were depleted of monocytes by incubation on plastic dishes overnight prior to stimulation (Exp. 1 and Exp. 2). In Exp. 3, blood E-lymphocytes were depleted of monocytes by incubation on plastic dishes for 1 hr. prior to stimulation. Tonsillar E_r⁺ lymphocytes were fractionated using Percoll gradients into dense (pellet) or buoyant (fraction 1) subsets (32).

5.4. USES OF ANTI-Bp50 LIGANDS AND Bp50

The ligands of the present invention may be used *in vivo* or *in vitro*, in their unmodified or modified forms to modulate immune responses. For example, the ligands themselves may be used as an "adjuvant" to increase an immune response to a vaccine or to increase the immune response of an immunosuppressed individual. Alternatively, if cytotoxins or anti-proliferative agents are coupled to the ligands, these modified ligands may be used to decrease an immune response, for example, in autoimmune disease or in transplant patients to obviate graft rejection. These modified ligands could also be used to treat malignancies that comprise cells or tumors which express the Bp50 antigen whether or not the malignancy is B-cell in origin.

- Both the ligands of the present invention and/or Bp50 itself can be used *in vitro*. Such applications include *in vitro* assays, such as immunoassays for the detection of cells which express the Bp50 antigen and/or for the detection of shed Bp50 antigen, if any, in body fluids. In this instance the ligand or Bp50 could be labeled with a radiolabel, fluor, enzyme, enzyme substrate, dye, etc. In addition, the ligands may be used to separate and/or identify cells which express the Bp50 antigen, in which case the ligand may be coupled to an immobile support, or to a fluor which can be used in a FACS (fluorescence activated cell sorter).

The various applications and uses of the ligands and Bp50 of the present invention are discussed in more detail below.

5.4.1. Bp50 RECEPTOR AND USES OF LIGANDS SUCH AS ANTI-Bp50 TO AUGMENT B-CELL PROLIFERATION

- Previous studies have suggested that the factors involved in the induction of B-cells from G_0 into the G_1 phase of the cell cycle are distinct from the factors or requirements for transit into the S phase. This model is based principally on studies showing that agents such as low doses of anti-Ig B-cell activation factors, or anti-Bp35 alone have little or no effect on B-cell proliferation. Yet, these same agents can drive B-cells to a point in cell activation where they are susceptible to growth factors. In contrast, growth factors such as BCGF or IL-2 alone have no effect on resting B-cells but do augment growth of activated B-cells.

- While the present invention is not to be limited to any theory or explanation, the results presented herein provide additional support for a model of distinct regulation of B-cell activation and growth steps. Here we have shown that activation and proliferation signals in human B-cells may be transmitted through distinct cell surface structures. Although anti-Bp35 mAb activated B-cells to enter the G_1 phase of the cell cycle, alone, it induced little or no proliferation. Anti-Bp50 mAb had the opposite effect: it could not activate B-cells, but when added even as late as 12-24 hours after activation could induce B-cell growth.

- The Bp50 molecule presumably could normally function as either a receptor for a ligand such as a soluble growth factor or for a signal mediated through cell-cell contact (i.e., a ligand found on the surface of another cell). Previous studies have identified several T cell-derived BCGFs that, like anti-Bp50, augment B-cell proliferation. Both high and low molecular weight forms of B-cell growth factors have been identified and different types have been shown to have additive effects (Kehrl, et al., 1984, Immunol. Rev. 18:75-96; Kishimoto, 1985, Ann. Rev. Immunol. 3:133-157; Swain, et al. 1983, J. Exp. Med. 158:822-835; Howard et al., 1984, Immunol. Rev. 78:185-210; Ambrus, et al., J. Clin. Invest. 75:732-739; Ambrus, 1985, J. Exp. Med. 162:1319-1335). Thus, Bp50 might be a receptor for one of these factors.
- With the exception of IL-2 receptors and the C3d receptor, the receptors on B-cells for growth signals have not yet been identified. The mAb AB-1 reacts with a B-cell marker expressed only on activated B-cells and blocks BCGF-dependent proliferation, and thus might recognize the BCGF receptor or a related structure. Bp50 appears to be distinct from the AB-1 marker since the AB-1 mAb does not block the binding of the G28-5 anti-Bp50 antibody, and unlike the G28-5 mAb, reacts only with activated B-cells (Jung, et al., 1984, J. Exp. Med. 160:1919-1924). Bp50 is on all B-cells, which based on absorption analysis and direct binding assays appears not to be the case for BCGF receptors. Our current data indicate that Bp50 and the receptor for low molecular weight BCGF are distinct structures. Using a rabbit heteroantiserum, Wang and coworkers (Wang, 1979, J. Exp. Med. 149:1424-1433) previously described a 54-kDa glycoprotein, gp54, that like Bp50 is expressed on all B-cells but at lower level on blood B-cells than tonsillar B-cells. It is possible, but unlikely, that the rabbit heteroantiserum and anti-Bp50 recognize the same or related structures: unlike anti-Bp50 mAb, the rabbit antiserum to gp54 alone was sufficient to stimulate B-cell proliferation.

- Anti-Bp35 alone, unlike anti-Bp50, can activate B-cells from G_0 to G_1 and thus can be referred to as an "activation" signal. Whether or not Bp35 functions only in early B-cell activation is not yet clear since anti-Bp35 antibodies can stimulate some B-cells to divide (Clark et al., 1985, Proc. Nat. Acad. Sci. USA 82:1766-1770). Similarly, Bp50 may not strictly function only as a "growth" signal: anti-Bp50 antibodies together with activation signals (anti-Bp35 or anti-u) not only augment proliferation but also augment the total number of B-cells entering G_1 (Table 2). In other words, anti-Bp50 as costimulant acts to promote the progression of both the activation

(G₀ to G₁) and growth (G to S) phases of the cell cycle. The BCGF used in these studies also had similar activity (Fig. 6C). Thus, anti-Bp35 and anti-Bp50 (or BCGF) appear to be most analogous to the "competence" and "progression" factors described in studies of fibroblast growth regulation. How B-cells respond to anti-Bp35 or anti-Bp50 clearly may depend on their state of differentiation or activation.

Here we have shown that two mAb, anti-Bp35 (a "competence" signal) and anti-Bp50 (a "progression" signal), together can induce substantial proliferation of highly purified B-cells in the absence of antigen or other known factors. The natural ligands for these structures are not yet known. However, since mAb to appropriate epitopes can mimic both soluble factors and signals mediated by cell-cell interactions, it may be possible to use appropriate combination of mAb to direct and regulate human B-cell proliferation or differentiation. This, in turn, will help in devising strategies *in vivo* for the control of human diseases such as B-cell malignancies, immunodeficiencies and certain autoimmune diseases.

The new monoclonal antibody, G28-5, that reacts with a single-chain polypeptide of approximately 50 Kd expressed on the surface of human B-cells is but a particular embodiment of the ligands of the present invention which can augment the proliferation of activated B-cells. Since human B-cell proliferation can be augmented similarly by T-cell-derived BCGFs including low- and high-molecular-weight BCGF we compared the activity of anti-Bp50 G28-5 with that of a BCGF preparation containing predominantly low-molecular-weight BCGF. Anti-Bp50 G28-5 and BCGF (low) were very similar in that they were costimulatory with the same activation agents (anti-Ig, anti-Bp35 and TPA) but were not costimulatory with each other or with IL-1 or IL-2. Furthermore, the activity of anti-Bp50 G28-5 was not dependent on its Fc domain since F(ab')₂ fragments of G28-5 were functionally active. This suggests that soluble anti-Bp50, like soluble BCGF, does not require Fc-receptor-bearing accessory cells to exert an effect. Furthermore, both anti-Bp50 and BCGF are effective only in the presence of an activation stimulus. In other words, anti-Bp50 and BCGF are not "competence" factors, but rather promote the "progression" of B-cells through the cell cycle.

While it is possible that Bp50 may function as receptor for a ligand such as a B-cell growth factor, several results suggest that Bp50 is not the receptor at least for the BCGF (low) used in this study: it is expressed on blood B-cells while BCGF (low) receptors apparently are not. Candidate structures for the BCGF (low) receptor, unlike Bp50, are also expressed only on activated B-cells. Furthermore, both normal and malignant B-cell populations differ in their responsiveness to anti-Bp50 versus BCGF (low) (Table 5 and Fig. 10). For instance, some B lymphomas proliferate in response to BCGF (low), but not in response to anti-Bp50. Finally, in a number of experiments, optimal concentrations of anti-Bp50 and BCGF together induced more proliferation than either one alone. Anti-Bp50 mimics the activity of other BCGF, such as BCGF (high) that are co-stimulatory with anti-IgM (Ambrus, et al., 1985, J. Exp. Med. 162:1319; Ambrus et al., 1985, J. Clin. Invest. 75:732). This suggests that Bp50 could function as the receptor for BCGF (high).

Although Bp50 may be a receptor for a soluble ligand, alternatively, Bp50 may function as a receptor for a cell-cell mediated signal that regulates BCGF receptor levels and/or autocrine production. Precedence for differentiation antigens serving as amplifiers of an autocrine-receptor pathway comes from studies with T cells. MAb to the Lp220 common leukocyte antigen augments proliferation by elevating IL-2 receptor expression on activated T cells (Ledbetter, et al., 1985, J. Immunol. 135:1819). An analogous mechanism may be operating with anti-Bp50 and expression of certain BCGF receptors. Bp50 and BCGF (low) apparently are under some coordinate control since, like IL-1 and IL-2 receptors, BCGF augments expression of Bp50 on certain leukemic cells. The Bp50 molecule also shares similarities with the Tp44 molecule that functions to influence IL-2 production. We and others have shown that the 9.3 anti-Tp44 antibody augments proliferation of T cells activated by anti-CD3 or TPA (Ledbetter, et al., 1985, J. Immunol. 135:2331; Hara, et al., 1985, J. Exp. Med. 161:1513). Similarly, anti-Bp50 augments the proliferation of B-cells activated by anti-Bp35 or TPA. The Tp44 signal functions by stimulating IL-2 production rather than by stimulating T cell growth. The Bp50 signal presumably could function in an analogous manner by stimulating B-cell autocrine production (Gordon, et al., 1984, *Nature, Lond.* 310:145).

5.4.2. MODIFIED LIGANDS USED FOR IMMUNOSUPPRESSION OR TREATMENT OF MALIGNANCIES

According to this embodiment, the ligand of the present invention can be modified by the attachment of an antiproliferative agent so that the resulting molecule can be used to kill cells which express the Bp50 antigen. Such modified ligands may be used in the treatment of autoimmune disease in order to suppress the proliferation of B-cells and thereby suppress the autoimmune response. These modified ligands can also be used to immunosuppress a transplant patient to prevent rejection of a graft. Accordingly, cytotoxic agents which are used for the suppression of immune responses can be attached to the ligands of the invention. When using

ligands which augment the proliferation of B-cells, an increased effect should result because the drug will be directed to proliferating B-cells.

- In another embodiment, the ligands of the present invention which are modified by the attachment of an antiproliferative agent can be used to treat malignancies in which tumor or cells express the Bp50 antigen. Attachment of these chemotherapeutic agents to the ligands of the invention should result in a greater specificity of the drug for the malignant cells. Moreover, a particular advantage should be obtained when treating a B-cell malignancy with a ligand coupled to a cytotoxin which is more effective in killing proliferating cells than non-proliferating cells; treatment with such a ligand should result in a potentiation of the action of the cytotoxin.
- 10 Accordingly, the chemotherapeutic agents or antiproliferative agents which can be coupled to the ligands of the present invention include but are not limited to the agents listed in Table 6 below which is derived from Goodman and Gilman, The Pharmacological Basis of Therapeutics, Sixth Edition, MacMillan Publishing Co., Inc, New York, pp. 1249-1313, 1980 which is incorporated by reference herein.

Table 6
Chemotherapeutic Agents Which Can be Coupled
to Anti-Bp50 Ligands

5	<u>Class</u>	<u>Type</u>	<u>Agent</u>	5
10	Alkylating Agent	Nitrogen Mustard	Mechlorethamine Cyclophosphamide Melphalan Uracil Mustard Chlorambucil	10
15		Ethylenimine Derivatives	Thiotepa	15
		Alkyl Sulfonates	Busulfan	
20		Nitrosoureas	Carmustine Lomustine Semustine Streptozocin	20
25		Triazenres	Dacarbazine	25
	Antimetabolites	Folic Acid Analogs	Methotrexate	
30		Pyrimidine Analogs	Fluorouracil Cytarabine Azaribine	30
35		Purine Anlogs	Mercaptopurine Thioguanine	35
40	Natural Products	Vinca Alkaloids	Vinblastine Vincristine	40
45		Antibiotics	Dactinomycin Daunorubicin Doxorubicin Bleomycin Mithramycin Mitomycin	45
		Enzymes	L-Asparaginase	

Miscellaneous Agents	Platinum Coordinated Complexes	Cisplatin	
5	Substituted Urea	Hydroxyurea	5
10	Methyl Hydrazine Derivative	Procarbazine	10
15	Adrenocortical Suppressant	Mitotane	15
Hormones and Antagonists	Adrenocorticosteroids	Prednisone	
20	Progestins	Hydroxyprogesterone caproate Medroprogesterone acetate Megestrol acetate	20
25	Estrogens	Diethylstilbestrol Ethinyl estradiol	25
30	Antiestrogen	Tamoxifen	30
	Androgens	Testosterone propionate Fluoxymesterone	
35	Radioactive Isotopes	Sodium phosphate $^{32}_{15}\text{P}$	35
40	Iodine	Sodium Iodide $^{131}_{53}\text{I}$	40

Any method known in the art can be used to couple the ligand to the chemotherapeutic or antiproliferative agent. Examples of such methods have been enumerated previously (see Section 5, *supra*). 45

5.4.3. OTHER USES OF LIGANDS AND Bp50

In addition to the therapeutic applications the ligands and Bp50 itself have other applications in both *in vitro* and *in vivo* diagnostic assays, separation schemes, etc. 50

The Bp50 receptor can be used to manufacture and/or design the ligands of the invention. Bp50 can also be used with the ligands of the invention in assays *in vitro* which require a standard to quantify the amount of Bp50 detected in a sample. Ultimately, Bp50, itself may be useful as a soluble factor which mediates immunity, e.g. a lymphokine.

In addition to therapeutic treatment and diagnostic assays, the ligands of the present invention could be used for identifying or separating cells which express the Bp50 antigen. In addition, if an appropriate radiolabel or radio-opaque compound is linked to the ligand, the ligand could be used for *in vivo* imaging of tumors which express the Bp50 antigen. Other uses should become apparent to those skilled in the art from the foregoing description. 55

60

6. DEPOSIT OF CELL LINES

The following hybridoma has been deposited with the American Type Culture Collection, Rockville, MD, and has been assigned the listed accession number:

Hybridoma ATCC Accession Number
G28-5 HB9110

- 5 The present invention is not to be limited in scope by the hybridoma deposited since the deposited embodiment is intended as a single illustration of one aspect of the invention and any cell lines which are functionally equivalent are within the scope of this invention. Indeed various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description and accompanying drawings. 5
- 10 Such modifications are intended to fall within the scope of the appended claims. 10

CLAIMS

1. A substantially pure ligand that binds to Bp50, a 50 Kilodalton B-cell surface antigen defined by monoclonal antibody G28-5.
- 15 2. A substantially pure ligand according to claim 1 which upon binding to an activated B-cell stimulates the activated B-cell to traverse the cell cycle so that proliferation of the B-cell is augmented. 15
3. A ligand according to either of claims 1 and 2 which comprises an antibody molecule or an Fv, Fab, F(ab')₂ or Fab' portion of the antibody molecule.
- 20 4. A ligand according to claim 3 in which the antibody molecule comprises a monoclonal antibody molecule or an Fv, Fab, F(ab')₂ or Fab' portion of the monoclonal antibody molecule. 20
5. A ligand according to claim 4 in which the monoclonal antibody molecule comprises G28-5, or any Fv, Fab, F(ab')₂ or Fab' portion thereof.
6. A ligand according to claim 4 in which the monoclonal antibody molecule has been 25 produced by a hybridoma cell line as deposited with the ATCC having accession no. HB9110, or a mutant recombinant or genetically engineered derivative thereof. 25
7. A ligand according to either of claims 1 and 2 which comprises a lymphokine.
8. A ligand according to claim 7 in which the lymphokine comprises a B-cell growth factor.
9. A ligand of either of claims 7 and 8 in which the lymphokine is on the surface of a cell.
- 30 10. A ligand according to any one of claims 1 to 9 which further comprises a compound coupled to the ligand. 30
11. A ligand according to claim 10 in which the compound coupled to the ligand comprises an antiproliferative agent.
12. A ligand according to claim 10 in which the compound coupled to the ligand comprises 35 an alkylating agent. 35
13. A ligand according to claim 10 in which the compound coupled to the liquid comprises an antimetabolite.
14. A ligand according to claim 10 in which the compound coupled to the ligand comprises an antibiotic.
- 40 15. A ligand according to claim 10 in which the compound coupled to the ligand comprises a vinca alkaloid. 40
16. A ligand according to claim 10 in which the compound coupled to the ligand comprises an enzyme.
17. A ligand according to claim 10 in which the compound coupled to the ligand comprises a 45 platinum coordinated complex. 45
18. A ligand according to claim 10 in which the compound coupled to the ligand comprises a radiosotope.
19. A ligand according to claim 10 in which the compound coupled to the ligand comprises a fluorescent compound.
- 50 20. A substantially pure 50 kilodalton B-cell surface antigen which is defined by monoclonal antibody G28-5. 50
21. A substantially pure 50 kilodalton antigen according to claim 20 which comprises a polypeptide.
22. A method for augmenting proliferation of B-cells comprising treating activated B-cells with 55 an effective dose of a liquid that binds to Bp50, a 50 kilodalton B-cell surface antigen defined by monoclonal antibody G28-5, so that activated B-cells traverse the cell cycle and proliferation is augmented. 55
23. A method according to claim 22 in which the B-cells were activated by treatment with an effective dose of a second ligand that binds to Bp35, a 35 kilodalton B-cell surface antigen, 60 so that the B-cell progresses from the G₀ to G₁ stage of the cell cycle. 60
24. A method according to either of claims 22 and 23 which is performed *in vivo*.
25. A method according to either of claims 22 or 23 is performed *in vitro*.
26. A method according to any one of claims 22 to 25 in which the ligand comprises an antibody molecule that binds to Bp50 or an Fv, Fab, F(ab')₂ or Fab' portion of the antibody 65 molecule that binds to Bp50. 65

27. A method according to any one of claims 22 to 25 in which the ligand comprises a monoclonal antibody molecule that binds to Bp50 of an Fv, Fab, F(ab')₂, or Fab' portion of a monoclonal antibody molecule that binds to Bp50.
28. A method according to claim 27 in which the monoclonal antibody molecule comprises G28-5, or any Fv, Fab, F(ab')₂, or Fab' portion thereof. 5
29. A method according to claim 27 in which the monoclonal antibody is produced by a hydridoma cell line as deposited with the ATCC having accession number HB9110, or a mutant, recombinant or genetically engineered derivative thereof.
30. A method according to any one of claims 22 to 25 in which the ligand comprises a lymphokine. 10
31. A method according to claim 30 in which the lymphokine comprises a B-cell growth factor.
32. A method according to claim 30 in which the lymphokine is on the surface of a cell.
33. A method according to any one of claims 22 to 25 in which the second ligand comprises an antibody molecule that binds to Bp35. 15
34. A method according to claim 33 in which the antibody that binds to Bp35 further comprises a monoclonal antibody.
35. A method according to claim 23 in which the activated B-cells are treated with the ligand that binds to Bp50 within about 12 hours after activation by the second ligand that binds to Bp35. 20
36. A method for suppressing proliferation of cells which express Bp50, a 50 kilodalton B-cell surface antigen defined by monoclonal antibody G28-5, comprising treating the cells which express Bp50 with an effective dose of a ligand that binds to Bp50, which ligand is coupled to an antiproliferative agent.
37. A method according to claim 36 in which the cells which express Bp50 comprise B-cells. 25
38. A method according to claim 36 in which the cells which express Bp50 comprise malignant cells.
39. A method according to any one of claims 36 to 38 which is performed *in vivo*.
40. A method according to any one of claims 36 to 38 which is performed *in vitro*.
41. A method according to claim 36 in which the ligand comprises an antibody molecule or an Fv, Fab, F(ab')₂ or Fab' portion of the antibody molecule. 30
42. A method according to claim 36 in which the antibody molecule comprises a monoclonal antibody molecule or an Fv, Fab, F(ab')₂ or Fab' portion of the monoclonal antibody molecule.
43. A method according to claim 42 in which the monoclonal antibody comprises G28-5, or any Fv, Fab, F(ab')₂, or Fab' portion thereof. 35
44. A method according to claim 42 in which the monoclonal antibody is produced by a hydridoma cell line as deposited with the ATCC having accession number HB9110, or any mutant, recombinant or genetically engineered derivative thereof.
45. A method according to claim 36 in which the ligand comprises a lymphokine.
46. A method according to claim 45 in which the lymphokine comprises a B-cell growth factor. 40
47. A method according to any one of claims 36 to 46 in which the antiproliferative agent comprises an alkylating agent.
48. A method according to any one of claims 36 to 46 in which the antiproliferative agent comprises an antimetabolite. 45
49. A method according to any one of claims 36 to 46 in which the antiproliferative agent comprises an antibiotic.
50. A method according to any one of claims 36 to 46 in which the antiproliferative agent comprises a vinca alkaloid.
51. A method according to any one of claims 36 to 46 in which the antiproliferative agent comprises an enzyme. 50
52. A method according to any one of claims 36 to 46 in which the antiproliferative agent comprises a platinum coordinated complex.
53. A method according to any one of claims 36 to 46 in which the antiproliferative agent comprises a radioisotope. 55
54. A substantially pure ligand as described in claim 1 substantially as hereinbefore specifically described.
55. A substantially pure surface antigen according to claim 20 substantially as hereinbefore specifically described.
56. A method for augmenting proliferation of B-cells substantially as hereinbefore specifically described. 60
57. A method for suppressing proliferation of B-cells substantially as hereinbefore described.